Optimizing GVHD Prophylaxis After Allogeneic Hematopoietic Cell Transplantation (NCT06799195)
A Phase II Randomized Trial to Optimize GVHD Prophylaxis After Allogeneic Hematopoietic Cell Transplantation in Older Adults With Hematological Malignancies: the PROMISE Trial
🩺 Plain-English Summary (8th-Grade Level)
This study will compare post-transplant health-related quality of life following the use of standard versus attenuated dose of post-transplant cyclophosphamide in addition to two-drug graft-versus-host disease (GVHD) prophylaxis among recipients of allogeneic hematopoietic stem cell transplant.
Who can join: Review the eligibility criteria below.
Location: University of Nebraska Medical Center — Omaha, Nebraska
Age range: 60 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- University of Nebraska Medical Center — Omaha, Nebraska
📞 Contact the Study Coordinator
Phone: (402) 559-4596
Email: taylora.johnson@unmc.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Hematological Malignancies
- A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma — Birmingham, Alabama
- Dose Escalation Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma — Birmingham, Alabama
- Feasibility of the Use of Weighted Blankets to Improve Sleep Among Patients With Hematological Malignancies — Houston, Texas
- Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma — Duarte, California
- Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Aggressive T Cell Hematological Malignancies — Houston, Texas
- A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma — Birmingham, Alabama
Explore by condition: All Hematological Malignancies clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.